Blood test may unlock targeted cancer drug for more patients

NCT ID NCT06129084

Ongoing Diagnosis Sponsor: Bernie Eigl Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a blood test can detect certain genetic changes (FGFR mutations) in patients with advanced bladder cancer better than the standard tissue biopsy. Currently, only patients with these mutations found in tumor tissue can get the drug erdafitinib. The blood test might catch mutations that tissue misses, potentially making more patients eligible for this targeted therapy. The study involves 260 participants and compares results from blood and tissue samples.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: blood test (ctDNA testing for FGFR mutations)
What this could lead to: If successful, this blood test could identify more patients with bladder cancer who might benefit from the targeted drug erdafitinib, improving treatment access.
What could go wrong: This is a diagnostic study, not a treatment trial. The blood test may not prove more accurate than tissue testing, and even if it is, it does not guarantee better outcomes for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

stage IVb bladder cancer transitional cell carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BLADDER CANCER METASTATIC UROTHELIAL CARCINOMA

Contacts and locations

Locations

Arthur J.E Child Comprehensive Cancer Centre

Calgary, Alberta, T2N 5G2, Canada
BC Cancer Agency

Vancouver, British Columbia, V5Z 4E6, Canada
CHU de Québec-Université Laval

Québec, Quebec, G1R 2J6, Canada
Cross Cancer Institute

Edmonton, Alberta, T6G 1Z2, Canada
London Health Sciences Centre

London, Ontario, N6A 5W9, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
Princess Margaret Cancer Centre

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.